CIDRAP newsletters options
Two Cochrane reviews this week covered the use of antibiotics for chronic obstructive pulmonary disease (COPD), which found benefits in some instances but overall precautions about prescribing them judiciously.
Saudi Arabia reported two more MERS-CoV cases, according to an update to its week 44 epidemiologic report today.
Neither of the patients had contact with camels, a factor known to raise the risk of contracting MERS-CoV (Middle East respiratory syndrome coronavirus). One patient is a 62-year-old man from the city of Omluj in Tabuk region in the northwest, and the other is a 53-year-old man from Riyadh in the central part of the country.
Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.
In its weekly update yesterday the US Centers for Disease Control and Prevention (CDC) said 36 more suspected acute flaccid myelitis (AFM) cases are under investigation, raising the national total since the first of the year to 191.
Researchers with the University of Pennsylvania Perelman School of Medicine have found that community-onset urinary tract infections (UTIs) caused by extended-cephalosporin-resistant Enterobacteriaceae (ESC-R EB) are associated with a sevenfold risk of clinical failure and an increase in inappropriate antibiotic therapy, according to a study today in Infection Control and Hospital Epidemiology.
The cases bring the total to 274, including 139 deaths.
Saudi Arabia's Ministry of Health (MOH) today reported one new MERS-CoV case for epidemiologic week 44. The MOH did not note any cases in epidemiologic week 43, which was last week.
The new case of MERS-CoV (Middle East respiratory syndrome coronavirus) occurred in a 74-year-old man from Riyadh who had contact with camels—a known risk factor for MERS transmission. The man is currently hospitalized.
Staphylococcus aureus hospitalizations at US pediatric hospitals fell by 36% from 2009 to 2016, with methicillin-resistant S aureus (MRSA) declining by 52%, with a corresponding drop in antibiotic use, according to a study today in Infection Control and Hospital Epidemiology.
With 6 new infections, the outbreak total reaches 257 cases and 164 deaths.
Save for the 2009-10 pandemic, the season was the worst in recent years.
Prior vaccination did not reduce the subsequent season's vaccine effectiveness in children 2 to 17 years old.
Cefiderocol has a novel way of penetrating the outer membrane of gram-negative bacteria, including resistant ones.
According to the latest weekly update from the Global Polio Eradication Initiative (GPEI), both Pakistan and Afghanistan recorded new polio cases in the past week.
Pakistan has two new cases of wild poliovirus type 1 (WPV1), in Sindh and Khyber districts. The case-patients experienced onset of paralysis on Sep 22 and 25, respectively. Officials have now reported six WPV cases in Pakistan this year, one more than at this time in 2017.
A Swedish study has found that a hospital stewardship program that restricted cephalosporin use was tied to reduced rates of Clostridioides difficile infection (CDI).
The new law would generally limit use of antibiotics to prevent disease in individual animals.
An investigation into 40 variant H3N2 (H3N2v) influenza cases in people exposed to pigs at three agriculture fairs in Maryland in September 2017 found that 30 (75%) occurred in people at high risk for flu complications. Researchers from the US Centers for Disease Control and Prevention and Maryland described their findings today in Morbidity and Mortality Weekly Report (MMWR).
In its daily update today the Democratic Republic of the Congo (DRC) health ministry reported four more lab-confirmed cases, three in the current outbreak epicenter in Beni and one in the city of Butembo.
Bacterial reads for unexplained sepsis were 1,000 times higher than with a different assay.
Today the US Food and Drug Administration (FDA) approved Xofluza (baloxavir marboxil) for the treatment of flu in patients ages 12 years and older who have been symptomatic for no more than 48 hours.
Xofluza is the first novel flu treatment approved by the FDA in nearly 20 years; the FDA approved the neuraminidase inhibitors oseltamivir and zanamivir in 1999.
